

%201.webp)


%201.webp)




LSPedia 的全球序列化系列
序列化不是一刀切的。由于美国、欧盟、亚洲和中东的规定各不相同,公司必须应对复杂的要求网络。您为全球合规做好准备了吗?
.avif)
欢迎来到 LspEdia,在这里,创新与奉献精神相结合。
如果你热衷于有所作为并在协作环境中茁壮成长,LspEdia 就是你的不二之选。



%201.webp)


%201.webp)




序列化不是一刀切的。由于美国、欧盟、亚洲和中东的规定各不相同,公司必须应对复杂的要求网络。您为全球合规做好准备了吗?
.avif)
如果你热衷于有所作为并在协作环境中茁壮成长,LspEdia 就是你的不二之选。

Pharmaceutical products in Oman are regulated by the Ministry of Health (MOH) through the Directorate General of Pharmaceutical Affairs and Drug Control (DGPA&DC). Oman has introduced barcode based identification requirements for medicines to improve product verification and strengthen pharmaceutical supply chain monitoring.
Oman aligns with GCC pharmaceutical identification standards, which encourage the use of GS1 compliant DataMatrix barcodes on pharmaceutical packaging. These barcodes enable unique identification of medicines and support verification during distribution and dispensing.
While Oman requires standardized barcode identification for medicines, the country does not currently operate a centralized national serialization reporting platform comparable to those implemented in some other GCC markets. Traceability oversight is primarily supported through product identification standards, supply chain documentation, and regulatory inspections.
Medicines marketed in Oman are expected to include a 2D DataMatrix barcode on the secondary packaging to support product identification within the pharmaceutical supply chain.
The DataMatrix barcode typically follows GS1 standards and includes the following data elements:
These identifiers allow each pharmaceutical package to be uniquely identified and verified during distribution and dispensing.
Human readable information printed on the packaging must correspond to the encoded barcode data.
2017–2018
Oman began aligning pharmaceutical packaging and identification practices with GS1 barcode standards used across GCC countries.
2019 onward
Barcode identification requirements were introduced to support improved product verification and anti-counterfeiting efforts.
Current Status
Pharmaceutical products distributed in Oman are expected to include GS1 compliant barcodes for identification, while broader national traceability infrastructure continues to evolve.
Since Oman does not operate a centralized serialization platform, there are no mandatory electronic reporting requirements for serialized supply chain events such as commissioning, shipment, receiving, or dispensing.
Pharmaceutical companies are expected to maintain internal traceability records that allow regulators to verify product movement across the supply chain when required.
Oman does not currently operate a centralized pharmaceutical serialization reporting system.
Manufacturers and importers are required to ensure that medicines carry standardized barcodes compliant with GS1 identification standards. Supply chain traceability is maintained through internal company systems and distribution records rather than through a national reporting platform.
Regulatory authorities may verify product identification and distribution documentation during inspections.
Oman’s current regulatory guidance focuses primarily on unit level product identification using DataMatrix barcodes.
Aggregation of pharmaceutical products at case or pallet level is not currently mandated by publicly available regulatory guidance. Pharmaceutical companies may implement aggregation internally to support logistics operations and warehouse management.
We invite you to learn more about how LSPedia can support your compliance and supply chain needs. For more information about our solutions, partnership opportunities, or to speak with one of our experts.